ScholarLens Back to search
2014•BMJRequires access

CDC promotes pre-exposure prophylaxis for HIV prevention

B. Roehr

Open publisher page 1 citations

Abstract

The US Centers for Disease Control and Prevention (CDC) has issued guidance for the broad use of pre-exposure prophylaxis for HIV prevention—better known by the shorthand PrEP—which builds on interim guidance issued in 2012. Truvada is a single pill containing two commonly used HIV drugs, tenofovir and emtricitabine, and it is the only product that currently carries a label indication for PrEP, although studies of other drugs for PrEP are under way. When taken daily it provides greater than 90% protection against HIV infection. The new guidance recommended PrEP as an option for four groups of people:

About this research paper

What this paper is about

The US Centers for Disease Control and Prevention (CDC) has issued guidance for the broad use of pre-exposure prophylaxis for HIV prevention—better known by the shorthand PrEP—which builds on interim guidance issued in 2012. Truvada is a single pill containing two commonly used HIV drugs, tenofovir and emtricitabine, and it is the only product that currently carries a label indication for PrEP, although studies of other drugs for PrEP are under way. When taken daily it provides greater than 90% protection against HIV infection. The new guidance recommended PrEP as an option for four groups of people:

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The US Centers for Disease Control and Prevention (CDC) has issued guidance for the broad use of pre-exposure prophylaxis for HIV prevention—better known by the shorthand PrEP—which builds on interim guidance issued in 2012. Truvada is a single pill containing two commonly used HIV drugs, tenofovir and emtricitabine, and it is the only product that currently carries a label indication for PrEP, although studies of other drugs for PrEP are under way. When taken daily it provides greater than 90% protection against HIV infection. The new guidance recommended PrEP as an option for four groups of people:

Key concepts: Emtricitabine, Pre-exposure prophylaxis, Tenofovir, Medicine, Human immunodeficiency virus (HIV), Pill, Interim, Disease control

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
CDC promotes pre-exposure prophylaxis for HIV prevention — Research Paper | ScholarLens